3D Systems and CollPlant Biotechnologies Collaborate to Accelerate Breakthroughs in Regenerative Medicine

Above: 3D bioprinted soft tissue implant with vascularization channels perfused with red ink. The implant was printed using 3D Systems’ stereolithography bioprinter and BioInk that is based on CollPlant’s rhCollagen/Image Credit: 3D Systems

3D Systems, one of the largest 3D printing companies in the world has joined forces with CollPlant Biotechnologies a developer of proprietary recombinant human collagen (rhCollagen) BioInk technology currently used for 3D bioprinting of tissues and organs to jointly develop tissue and scaffold bioprinting processes for third party collaborators.

Both the companies have signed a joint development agreement intended to play a pivotal role in advancing and accelerating breakthroughs in the biomedical industry. 

Recognising an Unmet Market Need

3D Systems and CollPlant recognised an unmet market need for a comprehensive solution to produce tissues and scaffolds for regenerative medicine applications. The companies intend to create integrated 3D bioprinting solutions comprised of state-of-the-art 3D bioprinters and BioInks to produce tissues and scaffolds. In accordance with the collaboration agreement, both companies may use a combination of 3D Systems’ printers, CollPlant’s BioInks, and new formulations of rhCollagen-based BioInks jointly developed by the companies, for their own products, as well as for deployments with third parties.  

[penci_related_posts taxonomies=”undefined” title=”Also Read” background=”” border=”Blue” thumbright=”yes” number=”4″ style=”grid” align=”none” displayby=”cat” orderby=”random”]

Speaking about how both the companies will work together and develop groundbreaking bioprinted tissue and scaffold technologies, Chuck Hull, Co-Founder and Chief Technology Officer at 3D Systems said, “3D Systems is excited to work with CollPlant to develop groundbreaking bioprinted tissue and scaffold technologies.

“We believe 3D printing to be a key technology for regenerative medicine, and this collaboration is one of many we are entering to play an integral role in this exciting field. Combining our innovative 3D printing technologies with CollPlant’s rhCollagen based BioInks has the potential to make a significant impact in bioprinting and regenerative medicine,” added Mr. Hull.

“We strongly believe that our proven rhCollagen is the finest building block for regenerative medicine tissues and scaffolds available today,” Yehiel Tal, Chief Executive Officer of CollPlant, stated.

“As the leading additive manufacturing printing solutions company, 3D Systems is the perfect partner for us. Together, we can offer the best combined technology for 3D bioprinting. We are honored to have established this important collaboration and we look forward to working together to advance 3D bioprinting technology to the commercial phase,” concluded Tal on collaborating with 3D Systems.